Our Mission
Mission
Our mission is to create vaccines and therapies for aging and aging-related diseases using artificial intelligence.
Problem
Lack of Preventative Therapy
One in two people will develop cancer, and half of them will die within ten years. There is no preventative therapy for cancer or other chronic diseases. Traditional biotech takes 20 years and $2 billion to bring a single drug to market for one disease at a time.
Solution
We integrate data from all cancers (34 types), one million drugs and biologic signatures, all human, viral, and bacterial proteins—including those found in the human microbiome, wastewater, and nutrition cycles—and vaccine discovery tools. Using in-house algorithms, we can predict with extraordinary accuracy which combination therapies work for specific cancers and design vaccines that protect against chronic diseases.
Validation
- We have validated our therapies in silico and rediscovered the standards of care for 17 cancers. Additionally, we have identified novel therapies and tested them in vitro and ex vivo. We discovered six combination therapies that completely eradicate cancer cells in 12 different cancer types and 17 subtypes—without harming healthy cells. These include some of the deadliest cancers, such as liver, pancreatic, stomach, colon, triple-negative breast cancer, lung cancer (including rare subtypes), kidney cancer, osteosarcoma, melanoma, and hematological cancers like leukemia and lymphoma.
Next Step: Vaccine Development
Currently, we are testing our cancer vaccine across 30 cancer organoids to demonstrate its efficacy in curing various types of cancer. We aim to show in animal models that pre-immunization with our vaccine can prevent the formation of any cancer type—even when cancer cells are injected. Our vaccine enables immune cells to detect and eliminate the very first cancer cells as they emerge.
Business Model & Customers
Our business model creates a unique opportunity to collaborate with pharmaceutical companies. A major challenge for pharma companies is losing market exclusivity when their drug patents expire. We address this by identifying new indications and novel combinations for their drugs, allowing them not only to maintain their sales but also to expand their market size up to fivefold by adding multiple new indications. In return, we offer a revenue-sharing model based on this added value.
Currently, we have identified new indications for drugs from major pharmaceutical companies like Pfizer and Merck, as well as smaller companies such as Cydex. Our approach enables them to transform existing therapies into blockbuster drugs, reaching more patients and expanding market access.
However, we also have the capability to commercialize our therapies and vaccines independently without direct partnerships with pharma, as we develop strong intellectual property around our innovations.
Competitive Advantage
Broader Patient Reach – Our therapies cover multiple indications, maximizing patient accessibility.
Higher Efficacy – They target core disease mechanisms more effectively.
Lower Side Effects – They require only a fraction of the standard dose.
Dual Benefit – They provide both therapeutic and preventative benefits, which is particularly critical for diseases like cancer.
Next-Generation Vaccines – Our vaccines will offer long-term prevention with zero side effects. Initially, they will be introduced for patients, but they can later be extended to protect healthy individuals from developing chronic diseases such as cancer.
Vision
We strongly believe that extending human lifespan is possible by scaling our approach to every chronic disease. This will unlock a massive, untapped market and revolutionize medicine, significantly improving human healthspan—potentially extending it to an estimated 150 years.